Introduction {#Sec1}
============

Diagnostic and therapeutic methods for cardiovascular diseases have been developed at a rapid pace in the past several decades. Various new drugs and devices for cardiovascular diseases have been introduced in the 21st century. Noninvasive diagnostic methods, such as cardio-ankle vascular index (CAVI), are one of the recent topics in the field of clinical diagnoses of cardiovascular diseases. In the near future, these non-invasive diagnostic methods may replace invasive methods for evaluating physiological characteristics of the cardiovascular system. Furthermore, upcoming drugs and devices will significantly improve clinical outcome in patients with severe cardiovascular dysfunction.

Although clinicians should take into consideration the physiological characteristics of the cardiovascular system for successful cardiovascular diagnosis and therapy, accurate evaluation of these characteristics such as ventricular end-systolic elastance, arterial elastance and impedance, and shear stress of vessels is sometimes difficult in the clinical setting because accurate measurements of physiological values, i.e., pressure, flow, and volume, require invasive methods such as catheterization. Upcoming noninvasive diagnostic devices will be helpful in evaluating these physiological characteristics in the near future. Physiological characteristics evaluated using such devices may be good predictors of cardiovascular prognosis. Furthermore, cardiovascular therapies based on cardiovascular physiology, such as mechanical ventricular unloading to reduce systolic pressure--volume area (PVA), may further improve therapeutic outcomes in patients with severe cardiovascular dysfunction.

In this review, we focus on the roles of cardiovascular physiology in recent diagnostic and therapeutic technologies for cardiovascular diseases. Four topics are selected from the viewpoint of medical specialists, an anesthesiologist, cardiologists, and a cardiovascular surgeon, who work in the forefront of clinical medicine: (1) left ventricle and systemic circulation, (2) right ventricle and pulmonary circulation, (3) coronary circulation, and (4) mechanical ventricular assist device (VAD). In the first section, we discuss how to evaluate left ventricular arterial coupling in the clinical setting, and report the usefulness of noninvasive diagnostic methods for its evaluation. In the second section, we review unique physiological characteristics of right ventricle and pulmonary circulation for clinical diagnosis and treatment of pulmonary arterial hypertension. In the third section, we discuss physiological and anatomical factors that affect graft patency after coronary artery bypass grafting (CABG). In the last section, we discuss the usefulness of mechanical ventricular unloading using VAD for acute myocardial infarction from the viewpoint of ventricular energetics.

Monitoring and clinical application of left ventricular arterial coupling (Ees/Ea) {#Sec2}
==================================================================================

Estimation of ventricular arterial coupling (Ees/Ea) is clinically useful in general anesthesia and critical care, since cardiac performance such as cardiac output and ejection fraction depends on Ees/Ea, and the efficacy of energetic transfer from the heart to the artery is also related to Ees/Ea. In a previous study, the left ventricular time-varying elastance curve was approximated by two straight lines, and left ventricular end-diastolic pressure was assumed to be zero for estimating Ees/Ea using four noninvasive parameters: end-systolic arterial pressure (Pes), diastolic arterial pressure (Pd), pre-ejection period (PEP), and ejection time (ET) \[[@CR1]\]. Pes was substituted by mean arterial pressure (Pm) to apply this estimation method to clinical monitoring. Although estimated values varied widely among individuals, the accuracy of Ees/Ea was high enough for clinical use, as discussed below.

Basics of Ees and Ea {#Sec3}
--------------------

A loop showing the pressure--volume relationship can be drawn using simultaneously measured left ventricular pressure and volume (Fig. [1](#Fig1){ref-type="fig"}). The slope of the line connecting the upper left of this loop and the volume-axis intercept (*V* ~0~) of the end-systolic pressure--volume relationship (ESPVR) is the end-systolic elastance (Ees), which expresses left ventricular systolic performance. The slope of the line connecting the upper left of the loop and the lower right corner (left ventricular end-diastolic volume; Ved) is the effective arterial elastance (Ea), which expresses ventricular afterload. The pressure at the intersection of these two lines is the counterbalance pressure of artery and ventricle (end-systolic pressure, Pes). As shown in Fig. [1](#Fig1){ref-type="fig"}, Ees and Ea are defined as follows:$$\documentclass[12pt]{minimal}
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Physiological and clinical significance of Ees/Ea {#Sec4}
-------------------------------------------------

Ees/Ea shows the efficiency of left ventricular contraction that pumps blood through the arteries. The heart usually contracts most efficiently when the carotid sinus baroreflex maintains a constant Ees/Ea against physiological disturbances \[[@CR2]\]. Therefore, any change in Ees/Ea may predict insufficiency of the cardiovascular control system.

Clinically, Ees/Ea can change even when arterial pressure is maintained, such as in states of septic shock and compensatory elevated peripheral vascular resistance when heart failure is exacerbated for a short time. Monitoring of Ees/Ea may predict changes in arterial pressure before they occur.

Problems of Ees/Ea monitoring in clinical settings {#Sec5}
--------------------------------------------------

The Ees (or ESPVR) has been determined by drawing multiple pressure--volume loops and a tangent line on the upper left of the multiple loops, when ventricular preload is decreased by inflating a balloon placed in the inferior vena cava with simultaneous high-fidelity measurements of left ventricular pressure and volume. This procedure is very invasive and not practical in clinical settings. To obtain Ees more easily, many less invasive single-beat estimation methods have been reported \[[@CR3], [@CR4]\], all of which require approximation and are not suitable for online processing.

Single-beat estimation of Ees/Ea without volume measurement {#Sec6}
-----------------------------------------------------------

To avoid high-fidelity volume measurement, Shishido et al. \[[@CR5]\] developed a framework of single-beat Ees estimation by approximating the time-varying elastance curve by two linear functions in the isovolumic contraction phase and ejection phase. As shown in Fig. [2](#Fig2){ref-type="fig"}a, Ees can be expressed as$$\documentclass[12pt]{minimal}
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Multiplying Eq. ([3](#Equ3){ref-type=""}) on both sides by (Ved-V~0~) yields:$$\documentclass[12pt]{minimal}
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Ees can be estimated using Pmax, Pes, and stroke volume (SV) as shown in Fig. [2](#Fig2){ref-type="fig"}b:$$\documentclass[12pt]{minimal}
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This framework requires no high-fidelity volume measurement. Ees can be obtained from SV and left ventricular pressure measurements. Hence, this framework allows calculation of Ees/Ea without volume measurements.

Using this framework, Ees/Ea can be expressed as:$$\documentclass[12pt]{minimal}
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Hayashi et al. \[[@CR1]\] simplified this method for further clinical application. When Ped = 0, Eq. ([5](#Equ5){ref-type=""}) will be simplified as:$$\documentclass[12pt]{minimal}
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Substituting Pmax in Eq. ([7](#Equ7){ref-type=""}) with Eq. ([5](#Equ8){ref-type=""}′) yields:$$\documentclass[12pt]{minimal}
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Since Pad can be replaced by arterial diastolic pressure (Pd), Eq. ([8](#Equ9){ref-type=""}) is expressed as:$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$${\text{Ees}}/{\text{Ea}} = {\text{Pd}}/{\text{Pes}} \times \left( {1 + k \cdot {\text{ET}}/{\text{PEP}}} \right) - 1$$\end{document}$$

The value of *k* has been reported to correlate with Ees/Ea in animal study \[[@CR1]\]. Using Ees/Ea, the value of *k* is approximated as:$$\documentclass[12pt]{minimal}
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Without volume parameters, Ees/Ea can be described using four parameters: Pes, Pd, PEP, and ET. However, since this method still requires left ventricular pressure measurement, it can only be used in patients undergoing cardiac catheterization.

Approximation to obtain Ees/Ea only from arterial pressure waveform {#Sec7}
-------------------------------------------------------------------

Because left ventricular pressure measurement is far more invasive than hemodynamic monitoring used in routine practice, mean arterial pressure (Pm) may be used as a surrogate of Pes \[[@CR6]\]. Ees/Ea obtained using Pm is shown in the following formula as (Ees/Ea)′.$$\documentclass[12pt]{minimal}
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A vascular screening system (VaSera VS-1000 or 1500, Fukuda Denshi, Tokyo, Japan) that performs limb lead electrocardiogram, phonocardiogram, and blood pressure measurements in bilateral upper and lower extremities was used to test this approximation. This system calculates arterial stiffness from the heart to the ankles (cardio-ankle vascular index: CAVI) and stenosis or occlusion of the arteries in lower limbs (ankle brachial pressure index: ABI). This system outputs the arterial pressure waveform, systolic blood pressure (Ps), Pm, Pd, PEP, and ET, in addition to electrocardiogram and phonocardiogram, on standard report paper. Using this device, the height of the arterial pressure waveform (h1) and the height of the arterial notch (h2) were measured manually, and Pes was obtained from pulse pressure and Pd using Eq. ([11](#Equ14){ref-type=""}) as shown below. The values obtained using Pes, expressed as Ees/Ea, and the values obtained using Pm, expressed as (Ees/Ea)′ were compared in 101 patients at University of Fukui Hospital **\[** [@CR7] **\]**, and the correlation is shown in Fig. [3](#Fig3){ref-type="fig"}, upper panels. Linear regression was performed for adjustment of (Ees/Ea)′ obtained using Pm, and adjusted Ees/Ea was calculated by Eq. ([12](#Equ15){ref-type=""}).$$\documentclass[12pt]{minimal}
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                \begin{document}$${\text{Ees}}/{\text{Ea}} = 0.70 \times \left( {{\text{Ees}}/{\text{Ea}}} \right)^{{\prime }}\, - \,0.22$$\end{document}$$ Fig. 3*Upper panels*, scatter plot (**a**) and Bland--Altman plot (**b**) to analyze the correlation between ventricular arterial coupling (Ees/Ea) obtained by the original method using end-systolic arterial pressure (Pes), expressed as Ees/Ea, and Ees/Ea approximated using mean arterial pressure (Pm), expressed as (Ees/Ea)′. *Lower panels*, scatter plot (**c**) and Bland--Altman plot (**d**) to analyze the correlation between ventricular arterial coupling (Ees/Ea) obtained using end-systolic arterial pressure (Pes), expressed as Ees/Ea, and the adjusted values of (Ees/Ea)′ \[approximated using mean arterial pressure (Pm)\] expressed as adj(Ees/Ea)′

Pm and other parameters measured were substituted in the simultaneous equations of Eqs. ([9](#Equ12){ref-type=""}′), ([10](#Equ13){ref-type=""}′), and ([12](#Equ15){ref-type=""}), and the results were expressed as adj(Ees/Ea)′. Pes and other parameters measured were substituted in the simultaneous equations of Eqs. ([9](#Equ10){ref-type=""}) and ([10](#Equ11){ref-type=""}), and the results were expressed as Ees/Ea. A good correlation between Ees/Ea and adj(Ees/Ea)′ was obtained as shown in Fig. [3](#Fig3){ref-type="fig"}, lower panels.

Measurement using CAVI device and standard values of Ees/Ea {#Sec8}
-----------------------------------------------------------

To obtain the normal range of Ees/Ea, CAVI were measured using a vascular screening system from 2675 men and 2287 women who underwent health checkup at Fukui-ken Saiseikai Hospital Checkup Center. At the same time, Ees/Ea was calculated using Pm, Pd, PEP, and ET, by Eqs. ([9](#Equ12){ref-type=""}′), ([10](#Equ13){ref-type=""}′), and ([12](#Equ15){ref-type=""}) (unpublished data).

The CAVI obtained from the subjects did not differ significantly from the distribution of normal values given in the instruction manuals of the instruments, indicating that the subjects were a healthy group. Although CAVI increases with aging, Ees/Ea is constant for all ages (Fig. [4](#Fig4){ref-type="fig"}), with an overall mean value and standard deviation of 1.2 ± 0.6.Fig. 4Age distribution of ventricular arterial coupling (Ees/Ea) in males (*open circles*) and females (*closed circles*). The overall mean value and standard deviation (SD) is 1.2 ± 0.6

Although ventricular contractility is influenced by various factors, such as heart rate and ventricular mass, Ees/Ea is a relatively stable index of ventricular performance. Heart rate affects ventricular contractility including Ees because of the positive force-frequency relationship \[[@CR8]\]. Since Ea changes parallel to Ees when heart rate changes, the influence of heart rate on Ees/Ea may be relatively smaller than that on Ees or Ea \[[@CR9]\]. There is a linear relationship between Ees and body mass \[[@CR9]\]. On the other hand, Ees/Ea has been reported to be preserved independent of heart size because the Windkessel parameters (characteristic impedance, peripheral resistance and total arterial compliance) also change according to the body mass \[[@CR10]\]. Therefore, a monitoring of Ees/Ea will be more beneficial than that of Ees or Ea alone because the gender difference is relatively small.

Limitations {#Sec9}
-----------

Several assumptions are made when estimating Ees/Ea with the four parameters; Pm, Pd, PEP, and ET, and several points should be kept in mind when using this estimation.

First, we assume zero Ped and use Pm as a surrogate of Pes in this estimation. Therefore, there is a possibility that Ees/Ea is overestimated when Ped is high. Furthermore, Ees/Ea will be miss-estimated when Pes is considerably higher than Pm. In these situations, several corrections of the four parameters are necessary. Although the absolute value of Ees/Ea obtained using this estimation is not identical to the true Ees/Ea measured by the conventional method by drawing left ventricular pressure--volume loops, continuous monitoring of intra-individual changes in Ees/Ea may be beneficial in general anesthesia and critical care.

Second, estimated values vary greatly. There may be errors in the measurements of the four parameters. Since their products and quotients are calculated, the errors will be amplified. However, the normal ranges obtained in this study from a large study population should have high reliability. Furthermore, variability in these values for individual estimations can be lowered by creating a consecutive approximating system with electrocardiographic, phonocardiographic, and arterial waveform measurements. Calculating mean values from consecutive data points will reduce the variability.

Summary {#Sec102}
-------

Ees/Ea can be monitored continuously using four parameters (Pm, Pd, PEP, and ET) that can be measured less invasively from arterial pressure waveform. The mean ± standard deviation of Ees/Ea was 1.2 ± 0.6 for all ages. Continuous monitoring of Ees/Ea is useful in general anesthesia and critical care.

Unique physiological characteristics of pulmonary circulation {#Sec10}
=============================================================

Pulmonary circulation has some unique features different from those of systemic circulation, leading to different appearances of pressure and flow waveforms in the pulmonary artery from those in systemic arteries. Several selective vasodilators of pulmonary vessels, such as prostaglandin *I* ~2~ and sildenafil, have been used to treat pulmonary hypertension in the last two decades. These medications dramatically change the hydraulic nature of pulmonary vessels. To use these drugs properly, clinicians need to have physiological knowledge about the functions of pulmonary vessels and the right ventricle, and their interaction. In this section, we explain the hydraulic nature of the pulmonary circulation, right ventricular contractility, and interaction of the right ventricle and pulmonary vessels (Ees/Ea), and discuss the methods to quantify these features.

Unique features of pulmonary circulation {#Sec11}
----------------------------------------

The lung is the only organ that receives the total blood volume ejected by the right ventricle. The SV of the right ventricle is equivalent to that of the left ventricle in a normal heart without shunt diseases. The absolute pressure and the amplitude of pulse pressure are smaller in the pulmonary circulation than in the systemic circulation, although the size of the arterial inlet (the main pulmonary trunk and the aorta) and volumetric flow are almost equivalent. This phenomenon is a result of lower resistive component against steady flow, lower impedance against oscillatory flow, and higher vascular distensibility in the pulmonary circulation than in the systemic circulation. The resistive component and impedance can be calculated quantitatively by computing the input impedance of the pulmonary artery. The distensibility of pulmonary vessels can be evaluated from the compliance or the pressure--flow relationship.

Pulmonary impedance {#Sec12}
-------------------

Pulmonary vascular resistance (PVR) is a hemodynamic index derived from the quotient of trans-pulmonary pressure over cardiac output. The PVR represents simple hydraulic vascular resistance in steady blood flow. However, because the blood flow is pulsatile, pulmonary input impedance is used to represent the pulsatile hydraulic vascular nature. The input impedance is computed by simultaneous recording of pressure \[*p*(*t*)\] (Fig. [5](#Fig5){ref-type="fig"}a) and flow \[*q*(*t*)\] (Fig. [5](#Fig5){ref-type="fig"}b). Harmonic decomposes of pressure \[*P*(*f*)\] and flow \[*Q*(*f*)\] are obtained by Fourier transform \[*F*(*x*)\].$$\documentclass[12pt]{minimal}
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Since each input impedance is a complex number, information regarding the magnitude (Fig. [5](#Fig5){ref-type="fig"}d) and phase (Fig. [5](#Fig5){ref-type="fig"}e) can be obtained. An augmentation of the reflected wave at a given frequency demonstrates a delay of phase \[[@CR11]\].

Caro and McDonald \[[@CR12]\] reported an important experimental study in 1961. They measured pulmonary impedance in isolated perfused lungs of rabbits, in which oscillated flow was generated by a sinusoidal pump that imposed a range of frequencies on steady flow. In this study, the modulus of pulmonary input impedance was measured at various frequencies. After their report, several studies examined pulmonary input impedance in dogs using harmonic analysis based on Fourier transform of the pressure and flow waveforms \[[@CR13], [@CR14]\]. The input impedance spectrum consists of impedance at 0-Hz frequency as PVR, characteristic impedance (Zc) at high frequencies usually measured between 4 and 8 Hz as large vessel stiffness, and an impedance curve at each frequency. Zc can also be measured in a time-domain manner (Fig. [5](#Fig5){ref-type="fig"}c) \[[@CR15]\]. Because each input impedance is a complex number, the input impedance spectrum contains information regarding the phase angle. An augmentation of reflected wave at each frequency denotes a delay of phase angle in the input impedance spectrum \[[@CR11]\]. In humans, pulmonary input impedance can be measured using a catheter with tip-mounted flow probe and pressure transducer \[[@CR16]\]. Zc was reported to be 20--37 dyn·s/cm^5^ in normal adults \[[@CR17]--[@CR22]\], and 46--124 dyn·s/cm^5^ in patients with pulmonary hypertension \[[@CR17], [@CR19], [@CR21], [@CR23], [@CR24]\] (Table [1](#Tab1){ref-type="table"}). Several studies also report measurement of pulmonary input impedance in clinical settings using pressure recorded by fluid-filled catheter systems and flow velocity simultaneously recorded by Doppler echocardiography \[[@CR24], [@CR25]\]. However, because signal delay and non-linear response caused by damping of the fluid-filled system \[[@CR26]\] are not considered in these studies, the modulus or phase angles measured by such methods may not be accurate.Table 1Pulmonary input impedance in normal adult subjects and patients with pulmonary hypertensionAuthorsYear*n*DiagnosisPAP (mmHg)PVR (dyn·s/cm^5^)Z1 (dyn·s/cm^5^)Zc (dyn·s/cm^5^)Normal subjectsMilnor et al. \[[@CR17]\]1969313.99723Murgo et al. \[[@CR18]\]19841014.97920Chen et al. \[[@CR19]\]1990819.31754934Slife et al. \[[@CR20]\]1990813.37322Laskey et al. \[[@CR21]\]19931014733822Noda et al. \[[@CR22]\]200612152414637Pulmonary hypertensionMilnor et al. \[[@CR17]\]19697MS40.234046Yin et al. \[[@CR23]\]19837HF37.645749Chen et al. \[[@CR19]\]19908COPD35.446916959Laskey et al. \[[@CR21]\]19938PPH5088038555Huez et al. \[[@CR24]\]200422PAH631282289124*COPD* chronic obstructive pulmonary disease, *HF* heart failure, *MS* mitral stenosis, *PAH* pulmonary arterial hypertension, *PAP* mean pulmonary artery pressure, *PPH* primary pulmonary hypertension, *PVR* pulmonary vascular resistance, *Z1* input impedance at 1st harmonic, *Zc* characteristic impedance

Distensibility of pulmonary vessels {#Sec13}
-----------------------------------

The simplest index of distensibility of the pulmonary vessels is the compliance *C* defined as SV divided by pulse pressure: \[[@CR27]\] $$\documentclass[12pt]{minimal}
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This index is comparable to the capacitance of the two-element Windkessel model, a simulator of the whole arterial tree. A decrease in pulmonary compliance is reported as an independent predictor of poor prognosis in patients with idiopathic pulmonary hypertension \[[@CR28]\]. However, because this index may be influenced by other parameters such as arterial stiffness and peripheral resistance, the time constant of pulmonary artery pressure \[[@CR29]\] may be a more feasible index of distensibility. Blockade of vascular inflow by valvular closure results in an exponential pressure fall induced by the flow from the capacitance to the resistive component. The time constant of the pulmonary arterial system is defined as the time interval required for pulmonary arterial pressure to fall from baseline value at time zero to 1/*e* of the value, where*e* is Napier's number. Although the time constant has been reported as constant in individuals \[[@CR29]\], it may become shorter with decreased pulmonary vascular bed in patients with pulmonary hypertension \[[@CR30], [@CR31]\].

Pulmonary pressure--flow relationship {#Sec14}
-------------------------------------

To prevent elevation in pulmonary arterial pressure, pulmonary vessels have autoregulatory systems such as passive distension, recruitment \[[@CR32]\], and vascular waterfall \[[@CR33]\] against increased pulmonary flow. The pressure--flow relationship may be useful to evaluate the autoregulatory function. A regression curve of pulmonary driving pressure versus pulmonary blood flow reflects the whole pulmonary reaction against increased flow \[[@CR34]\]. Because pulmonary arterial pressure is dependent on flow, comparison between PVR should be interpreted with caution especially in the lower range of cardiac output \[[@CR35]\]. If pulmonary hypertension exists, this regression curve will become steeper, reflecting impaired pulmonary vascular autoregulation against increased flow (Fig. [6](#Fig6){ref-type="fig"}). The normal range of the slope of mean pulmonary arterial pressure versus cardiac output is between 0.5 and 2.5 mmHg·min/l \[[@CR36]\]. However, because pulmonary arterial pressure is elevated partly as a result of elevated left atrial pressure in response to increased pulmonary blood flow or elevated left ventricular end-diastolic pressure during exercise, this index may not directly reflect pulmonary vascular autoregulation.Fig. 6The pressure--flow relationship of the pulmonary artery. In normal subjects, increase in trans-pulmonary pressure (PAP-PAOP) is suppressed in the high flow range. The angles of *θ*1 and *θ*2 indicate pulmonary artery resistance (PVR) at cardiac output of 2 and 10 l/min, respectively. PVR varies with change in cardiac output even in the same subject \[[@CR33]\]. In patients with pulmonary hypertension (PH), this regression curve becomes steeper, reflecting impaired pulmonary vascular autoregulation against increased flow. *PAP* mean pulmonary artery pressure, *PAOP* pulmonary artery occlusion pressure

Unique features of the right ventricle {#Sec15}
--------------------------------------

The morphology of the right ventricle is complex and completely different from that of the left ventricle. The cavity of the normal right ventricle has a trigonal pyramidal shape, and consists of three parts; the inlet segment, trabecular component, and outflow tract. The trabecular component consists of coarse trabeculated myocardium composed of thin-layered linear fibers extending to the apex, and intra-ventricular septal myocardium shared with the left ventricle. Right ventricular contraction is caused by longitudinal shortening of myocardial fibers in the right ventricular free wall. The SV of the right ventricle is equivalent to that of the left ventricle, but the stroke work is approximately 25% of that of the left ventricle because of low resistance of the pulmonary vasculature \[[@CR37]\]. Any increase in right ventricular preload will cause chamber dilatation and tricuspid regurgitation, resulting in annular dilatation.

Contractility of the right ventricle {#Sec16}
------------------------------------

When the right ventricle is simulated by a time-varying elastance model \[[@CR38]--[@CR40]\], Ees represents ventricular contractility \[[@CR41]\]. However, real-world evaluation of Ees requires the use of a conductance catheter. The conductance catheter technique is based on the assumption that the electrical field produced by the catheter is homogeneous and parallel to the longitudinal axis of the ventricle, and the current created by the excitation electrodes on the catheter is localized within the ventricular cavity \[[@CR42]\]. To draw the pressure--volume loop of the right ventricle \[[@CR43]\], preload interventions by vena cava occlusion or fluid overload are required. Because of the risk of hemodynamic collapse, this method may not be suitable for clinical application in patients with cardiovascular diseases such as pulmonary hypertension.

Another method to estimate Ees using left ventricular Pmax obtained from the pressure curve of a single ejecting contraction was proposed by Sunagawa and colleagues \[[@CR44]\]. In brief, Pmax is estimated using an extrapolated sine curve fitted to the left ventricular pressure during the isovolumic period (Fig. [7](#Fig7){ref-type="fig"}a). Currently, this method is extended to the right ventricular pressure curve \[[@CR45]\]. Ees of the right ventricle can be estimated by combining the right ventricular Pmax, Pes and SV (Fig. [7](#Fig7){ref-type="fig"}b).$$\documentclass[12pt]{minimal}
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                \begin{document}$${\text{Ees}} = \left( {{\text{Pmax}} - {\text{Pes}}} \right)/{\text{SV}}$$\end{document}$$ Fig. 7Computation of end-systolic elastance (Ees) of the right ventricle. **a** Peak isovolumic pressure (Pmax) from a given single contraction of the right ventricle is estimated from the extrapolated sine curve (*dashed line*) using the isovolumic pressure (*shadowed periods*) \[[@CR42], [@CR43]\]. **b** Ees is estimated by combining the Pmax, the right ventricular end-systolic pressure (Pes) and stroke volume (SV) \[[@CR43]\]. The estimated pressure--volume loop of the right ventricle is drawn with a *dashed line*.*Ea* effective arterial elastance, *HMP* hydromotive pressure, *ICT* isovolumic contraction time, *IRT* isovolumic relaxation time

The value of Ees was reported to be 1.1 mmHg/ml in normal subjects and 3.6 mmHg/ml in patients with pulmonary hypertension with mean pulmonary arterial pressure of 57 mmHg \[[@CR46]\]. However, there are several methodological limitations to evaluate Ees of the right ventricle, such as the difficulty in determining Pes on pressure waveform, prolonged ejection after end-systole under the condition of low pulmonary arterial pressure, difficulty in determining the troughs of the extrapolated sine curve in short isovolumic contraction and relaxation phases \[[@CR47]\], and lack of data of ejected volume after end-systole and regurgitant volume of the tricuspid valve.

Right ventricle-pulmonary arterial coupling {#Sec17}
-------------------------------------------

The ejected blood generates a pressure in the vascular tree, and this pressure behaves as ventricular afterload. In the pulmonary circulation, the right ventricular performance interacts closely with the hydraulic nature of the pulmonary artery \[[@CR48]--[@CR50]\]. As in the case of the left ventricle, the SV of the right ventricle is determined by the balance between ventricular contractility and afterload. The afterload can be evaluated as effective arterial elastance \[[@CR51]\], which is defined as Pes divided by SV. The coupling efficiency is defined as Ees/Ea \[[@CR52]\]. An animal study reported the normal value of Ees/Ea of the right ventricle in anesthetized dogs to be 1.64 \[[@CR45]\]. The normal Ees/Ea of the right ventricle in humans has also been reported. While the estimated Ees/Ea is 1.9 in normal subjects, it decreases to 1.1 in patients with pulmonary hypertension with mean pulmonary arterial pressure of 57 mmHg \[[@CR46]\]. This fact may demonstrate the existence of a potential mismatch between right ventricular contractility and afterload in patients with pulmonary hypertension.

Summary {#Sec18}
-------

Although several hemodynamic parameters such as cardiac output, mean pulmonary pressure, and PVR are used to represent the hydraulic nature of the pulmonary circulation, simultaneous recording of pulmonary arterial pressure and flow waveforms is essential to obtain precise information of the hydraulic nature of the pulmonary circulation, such as pulmonary input impedance. Moreover, contractility of the right ventricle and coupling efficiency (Ees/Ea) can be measured by analyzing the pressure waveform of the right ventricle. Recording of pressure and flow waveform at high frequency without damping noise is necessary to achieve this analysis. Careful considerations of the physiological characteristics of the pulmonary circulation will optimize medical care for pulmonary hypertension.

Physiological and anatomical factors affecting vein graft patency after coronary artery bypass grafting {#Sec19}
=======================================================================================================

The coronary circulation is essential for normal functioning of the left and right ventricles. The stenosis or occlusion of coronary arteries leads to ischemic heart diseases and requires intravascular or surgical intervention. Coronary artery bypass grafting (CABG) is still more beneficial than percutaneous coronary intervention (PCI) in patients with triple-vessel coronary artery disease and in diabetic patients with multi-vessel disease \[[@CR53], [@CR54]\]. The clinical outcome after CABG is contingent on graft patency \[[@CR55]--[@CR57]\]. Although saphenous vein graft (SVG) is widely used, its patency is poorer compared with internal thoracic artery graft \[[@CR55], [@CR58]\]. Other than technical errors, saphenous vein graft failure develops in three distinct phases; (1) thrombosis causing early graft failure, (2) intimal hyperplasia leading to stenosed lumen and graft failure by 1 year, and (3) atherosclerosis occurring subsequent to intimal hyperplasia \[[@CR59], [@CR60]\]. Accurate intraoperative assessment of vein graft failure is important because technical errors can be corrected in the operative room. Also, predicting mid-term graft failure would be helpful for clinicians. In this section, we review how physiological and anatomical factors correlate with vein graft patency.

Physiological factors {#Sec20}
---------------------

### Wall shear stress {#Sec21}

Wall shear stress is known to play an important role in the process of intimal hyperplasia \[[@CR61], [@CR62]\]. The development of anastomotic intimal hyperplasia has been reported to connote a physiological adaptation of the vascular wall to lowered shear stresses prevailing in areas of flow separation \[[@CR63]\]. Wall shear stress is also independently associated with intimal hyperplasia in saphenous vein \[[@CR64]\]. When vein grafts adapt to the arterial system, i.e., high pressure system, vein grafts exposed to low shear stress respond primarily through enhanced intimal thickening, but high-shear-stress grafts adapt through enhanced outward remodeling \[[@CR65]\]. Therefore, an assessment of wall shear stress is essential for predicting graft patency.
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                \begin{document}$$\tau \left( y \right) = \mu \cdot \frac{\partial u}{\partial y}$$\end{document}$$where *μ* is the dynamic viscosity, *u* is the flow velocity along the boundary, and *y* is the distance from the boundary. Wall shear stress (*τ* ~w~ = *τ*(0), Fig. [8](#Fig8){ref-type="fig"}) in blood vessels is simplified by the Hagen-Poiseuille's law \[[@CR66]\]:$$\documentclass[12pt]{minimal}
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                \begin{document}$$\tau_{\text{w}} = 32 \cdot \mu \cdot \frac{Q}{{\pi \cdot d^{3} }} = 8 \cdot \mu \cdot \frac{{u_{\text{ave}} }}{d}$$\end{document}$$where *Q* is the mean volumetric flow rate, *u* ~ave~ is the average velocity, and *d* is the vessel diameter. Therefore, the monitoring of graft volumetric flow or flow velocity with graft diameter, as an index of shear stress, can predict the volume of hyperplasia that may lead to graft failure by 1 year after CABG.Fig. 8Schematic representation of wall shear stress. Wall shear stress (*τ* ~w~) is calculated as shear stress at *y* = 0. *μ* dynamic viscosity, *u*(*y*) flow velocity along the boundary, *y* the distance from the boundary

To evaluate shear stress more accurately, it is necessary to solve the Navier--Stokes equations for the velocity vector (***u***) \[[@CR67]\]. When the blood is assumed to be incompressible (*ρ* = constant), the Navier--Stokes equations are described as below:$$\documentclass[12pt]{minimal}
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                \begin{document}$$\nabla \cdot \varvec{u} = 0$$\end{document}$$where *ρ* is the blood density, *ν* is the kinematic viscosity (*ν* = *μ*/*ρ*), and *p* is the pressure. However, there has been a principal difficulty in the general solution of the Navier--Stokes equations. Recent development of computer technology enables us to solve these equations numerically even in a desktop computer using a commercial-based computational fluid dynamics (CFD) software \[[@CR68]\]. Therefore, preoperative CFD simulation with computed tomographic images or magnetic resonance imaging images of coronary artery may accurately predict wall shear stress after operation. However, this does not consider technical errors, such as stenosed anastomosis. Therefore, intraoperative methods, such as a transit time flowmetry, may be more beneficial for surgeons.

### Graft flow {#Sec22}

Shear stress per se is not a parameter of clinical interest. Instead of shear stress, mean graft flow is usually measured and recorded in operative rooms. A transit time flowmetry that is easy and quick to operate is widely used all over the world for intraoperative assessment of graft blood flow. Previous studies revealed that lower graft flow was strongly associated with graft failure \[[@CR69]--[@CR72]\]. Technical errors such as bypass twist, kinking, and/or stenosed anastomosis can be detected easily during operation. However, the cut-off value for graft revision is difficult to determine. In the case of high-quality anastomosis, the volumetric flow depends largely on myocardial oxygen demand \[[@CR73]\]. Furthermore, graft volumetric flow is affected by various factors including blood pressure, graft size, heart rate, myocardial volume, run-off, use of cardiopulmonary bypass, degree of hemodilution, degree of proximal stenosis in target vessel, and type of transit time flowmeter \[[@CR74], [@CR75]\]. With an inappropriate cut-off value, the result of transit time flowmetry sometimes suggests unnecessary revision \[[@CR72], [@CR76]\]. Notwithstanding, volumetric flow was reported to predict mid-term graft failure \[[@CR72], [@CR77]\]. This may be because graft volumetric flow partially reflects wall shear stress as described above. Because wall shear stress is inversely proportional to the cube of vessel diameter, at the same volumetric flow, larger grafts have lower shear stress resulting in more hyperplasia \[[@CR61], [@CR62], [@CR78]\].

### Flow patterns {#Sec23}

Pulsatility index (PI), a common index of flow pattern, is also measured using transit time flowmetry. PI is derived from the difference between maximum (*Q* ~max~) and minimum flow (*Q* ~min~) divided by the mean flow (*Q* ~m~) \[[@CR79]\].$$\documentclass[12pt]{minimal}
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High PI is associated with graft failure \[[@CR69], [@CR70], [@CR80]\], indicating poor quality of the anastomosis with high anastomotic resistance. Although PI is recognized as an index of downstream resistance, its physiological meaning is still under dispute \[[@CR81]\]. Mathematical models demonstrate that PI has no distinctive physiological meaning by itself \[[@CR81]\] and there is a complex relationship between PI and multiple hemodynamic variables \[[@CR82]\]. Therefore, further investigations are needed to clarify physiological meanings of PI.

Other indices of flow pattern, e.g., the percentage of diastolic flow or backward flow, are also reported to be associated with graft patency \[[@CR69]--[@CR71], [@CR77]\]. However, physiological meanings of these indices are still under dispute as well as PI.

Anatomical factors {#Sec24}
------------------

### Location of anastomosis {#Sec25}

The blood flow to the left coronary artery usually has a diastolic dominant flow pattern, while a bimodal flow pattern (systolic and diastolic) is observed in the right coronary artery \[[@CR83]\]. Bypass grafts to the right coronary artery become occluded more frequently than those to the left coronary artery \[[@CR78], [@CR84]\]. Because temporal gradients in shear stress induce more intimal hyperplasia than spatial gradients \[[@CR85]\], the bimodal flow pattern in the right coronary system likely contributes to more hyperplasia compared with the diastolic dominant flow pattern in the left coronary system.

### Degree of stenosis in target vessels {#Sec26}

Another important anatomical factor is the severity of proximal coronary stenosis in a target vessel. A CFD simulation demonstrated that, in the CABG model without proximal coronary stenosis, wall shear stress was markedly decreased in the vicinity of anastomosis and in the graft \[[@CR86]\]. Less severe proximal stenosis was clinically reported to be associated with diminished patency in SVGs and radial artery grafts, with a more prominent effect seen in radial arteries \[[@CR87]\]. In addition to less shear stress, mild stenosis in proximal coronary artery is more likely to cause spasm of radial artery grafts \[[@CR88], [@CR89]\].

### Graft size and harvest techniques {#Sec27}

Because graft diameter is inversely proportional to wall shear stress, small vein graft is at lower risk of hyperplasia and graft failure \[[@CR78], [@CR90]\]. Graft size depends on the harvest site and harvest technique. In a previous study, vein grafts harvested from the lower legs had better patency than those from the thigh \[[@CR91]\]. In addition to choosing the appropriate harvest site, avoiding manual distension of vein grafts commonly practiced in conventional harvest techniques may improve graft patency. As for internal thoracic arteries, harvest method has no impact on graft flow or graft patency \[[@CR73], [@CR92]\]. In contrast, previous small studies showed that a no-touch harvesting technique for SVG provided excellent patency compared with conventional method \[[@CR91], [@CR93]\]. In the no-touch technique, the vein is harvested atraumatically along with a pedicle of fat, and is not manually distended. In addition to integrity of the vein wall and vaso vasorum, the size of grafts harvested by the non-touch method is more favorable compared with conventional method. An on-going multicenter clinical trial (SUPERIOR-SVG, clinicaltrials.gov: NCT01047449) \[[@CR94]\] may show superiority of the no-touch harvesting technique.

Other factors {#Sec28}
-------------

In clinical settings, secondary prevention therapy is also an important factor for graft patency. Recent studies revealed that dual antiplatelet therapy improved SVG patency or inhibited progression of native coronary disease after CABG \[[@CR95]--[@CR97]\]. These secondary prevention therapies may affect physiological factors through the modulation of endothelial functions.

Summary {#Sec29}
-------

Both physiological and anatomical factors predict vein graft patency. Lower graft flow, larger SVG, conventional harvest techniques, lower percentage of diastolic flow, higher percentage of backward flow, higher PI, and bypass to the right coronary artery are associated with worse graft patency during the early to mid-term period. In principle, accurate evaluation of wall shear stress is essential for predicting mid-term graft failure. At least, graft diameter should be taken into consideration to improve the ability of intraoperative graft flow measurement.

Mechanical unloading by left ventricular assist device for acute myocardial infarction {#Sec30}
======================================================================================

Over the past few decades, significant progress has been made in left ventricular assist devices (LVADs). Especially, the progress in percutaneous LVADs has allowed their use in acute clinical settings such as temporary hemodynamic support in high-risk percutaneous coronary intervention and cardiogenic shock. LVAD decreases myocardial oxygen consumption (MVO~2~) through mechanical unloading of the left ventricle. Since imbalance between oxygen supply and demand is the fundamental pathophysiology of myocardial infarction (MI), LVAD has been proposed as a novel strategy to minimize myocardial damage resulting from acute MI. In this section, we introduce a new therapeutic option of LVAD in the management of acute MI and discuss the physiological and mechanical impact of LVAD in terms of cardiac energetics.

Development of left ventricular assist device {#Sec31}
---------------------------------------------

In 1966, DeBakey \[[@CR98]\] first implanted an LVAD for the treatment of postoperative cardiogenic shock. The LVAD improved cardiac function and was successfully removed after a week. LVADs were initially developed as a bridge to heart transplantation for patients with end-stage heart failure. However, they have been increasingly used as a destination therapy or bridge to recovery. The REMATCH trial demonstrated a significant survival advantage and improvement of quality of life in patients with end-stage heart failure treated with first-generation, implantable, pulsatile flow LVAD compared with optimal medical management \[[@CR99]\]. Second-generation implantable LVADs that circulate blood in a continuous flow fashion using an internal rotor are smaller and have proven to be more durable than pulsatile first-generation LVADs. Clinical trial of HeartMate II, a second-generation implantable axial continuous flow pump, concluded that the device provides effective hemodynamic support for at least 18 months in patients awaiting transplantation, with improved functional status and quality of life \[[@CR100]\]. Recently, temporary LVADs that can be placed percutaneously by cardiologists in the catheterization room are also available (Fig. [9](#Fig9){ref-type="fig"}) \[[@CR101]\]. Percutaneous LVADs such as Impella^®^ (Abiomed, Inc.; Danvers, MA, USA; Fig. [9](#Fig9){ref-type="fig"}a) and TandemHeart™ (Cardiac Assist, Inc.; Pittsburgh, PA, USA; Fig. [9](#Fig9){ref-type="fig"}b), have become essential tools in the treatment of cardiogenic shock \[[@CR102]\] and high-risk percutaneous coronary intervention \[[@CR103]\].Fig. 9Schematic representation of two percutaneous LVADs. Impella^®^ (**a**) pulls blood from the left ventricle into the ascending aorta. TandemHeart™ (**b**) pumps blood from the left atrium into one or both femoral arteries

Left ventricular assist device for the treatment of myocardial infarction {#Sec32}
-------------------------------------------------------------------------

Despite advances in early reperfusion therapy for patients with MI, 10% of patients die in the acute phase and about 30% develop heart failure in the long term \[[@CR104]\]. Since the presence of residual myocardial damage leads to heart failure, there exists an unmet need to develop better cardio-protective strategies that improve the long-term outcome after MI. LVAD supports hemodynamics and unloads the left ventricle. In addition, the development of percutaneous LVADs allows application of the device to acute clinical setting.

The concept of left ventricular unloading using percutaneous LVAD to protect the ischemic left ventricle has been proposed and several animal and clinical studies have been conducted. Meyns and colleagues \[[@CR105]\] reported that left ventricular unloading using Impella^®^ significantly reduced the infarct size in a sheep model of myocardial ischemia--reperfusion. Using an ischemia--reperfusion model, Kapur and colleagues \[[@CR106]\] showed that left ventricular unloading by TandemHeart™ activated the RISK (reperfusion-injury salvage kinase) pathway that protects the myocardium from apoptosis, and significantly reduced infarct size despite longer ischemic exposure. In clinical trials, Engström and colleagues \[[@CR107]\] reported the long-term effects of 3-day support with Impella 2.5^®^ on left ventricular ejection fraction (LVEF). They concluded that Impella 2.5^®^ significantly improved the recovery of LVEF. In addition, the USpella registry showed that initiation of LVAD support using Impella 2.5^®^ prior to reperfusion was associated with more complete revascularization and improved survival in the setting of refractory cardiogenic shock complicating acute MI \[[@CR108]\]. Based on these findings, Kapur and colleagues \[[@CR106]\] proposed a novel concept of initial mechanical unloading of the ischemic left ventricle before coronary reperfusion, so-called "door to unloading", and emphasized its importance.

Mechanical impact of left ventricular assist device on left ventricle {#Sec33}
---------------------------------------------------------------------

Understanding the underlying pathophysiology is a prerequisite to optimal use of LVAD treatment in MI patients. Systolic PVA, a specific area circumscribed by the end-systolic and end-diastolic pressure--volume relation curves and the PV loop (Fig. [10](#Fig10){ref-type="fig"}a), represents the total mechanical work of each ventricular contraction. Since PVA tightly couples with myocardial oxygen consumption (MVO~2~) \[[@CR109]\], the impact of LVAD support on MVO~2~ can be revealed by examining PVA under the fixed heart rate (HR) condition. In this framework, LVAD decreases preload by withdrawing blood from the left ventricle and increases afterload by infusing blood into the aorta. Therefore, the impact of LVAD on PVA depends on the balance between the decreased preload and increased afterload. A theoretical analysis indicates that partial LVAD support, where the left ventricle remains ejecting, does not significantly decrease PVA \[[@CR110]\]. In this setting, the impact on PVA is almost the same as that of extracorporeal membrane oxygenation \[[@CR111], [@CR112]\]. In contrast, total LVAD support, where the left ventricle no longer ejects, markedly reduces left ventricular pressure and volume, thereby significantly decreases PVA (Fig. [10](#Fig10){ref-type="fig"}b).Fig. 10**a** Pressure--volume area (PVA) indicated by the*gray area* is the sum of external work (EW) and potential energy (PE). PVA couples with myocardial oxygen consumption. **b** Theoretical analysis of the impact of left ventricular assist device (LVAD) on the pressure--volume (PV) loops. The *loop in solid line* represents the baseline PV loop. In partial LVAD support, LVAD decreases left ventricular end-diastolic volume and increases mean arterial pressure, which in turn increases end-systolic volume (*loop in dashed line*). On the other hand, total LVAD support markedly lowers left ventricular pressure to below the arterial pressure, yielding an extremely small PVA (*loop in bold line*). *EDPVR* end-diastolic pressure volume relation, *ESPVR* end-systolic pressure volume relation, *V0* the volume-axis intercept of ESPVR, *Vu* the volume-axis intercept of EDPVR

Although some drugs such as β-blockers \[[@CR113]\] and angiotensin-converting enzyme (ACE) inhibitors \[[@CR114]\] have been known to reduce MVO~2~ and decrease the infarct size in MI or ischemia--reperfusion, these drugs do not stabilize the hemodynamics in an acute MI setting. LVAD is the only modality that markedly reduces PVA while stabilizing systemic hemodynamics. Thus, total LVAD support minimizes PVA and MVO~2~ of the left ventricle, and maximally reduces infarct size in MI patients without compromising systemic hemodynamics \[[@CR110]\]. Considering these physiological and mechanical effects of LVAD on the left ventricle, LVAD has promising potential in MI treatment. In addition, heart rate is also the major component of MVO~2~ \[[@CR115]\]. Therefore, the combination of bradycardic agent, e.g., If channel inhibitor, and LVAD will attribute to the further reduction of MVO~2~ and infarct size in MI. Appropriate left ventricular unloading will maximize the beneficial impact of LVAD in the clinical setting of acute MI.

Conclusions {#Sec34}
===========

We reviewed four selected topics of cardiovascular physiology. This review may leave several messages for clinicians. First, a noninvasive monitoring method of arterial stiffness may be useful in evaluating the left ventricular arterial coupling (Ees/Ea) in the clinical setting. Second, careful consideration of the unique physiological characteristics of pulmonary circulation may be essential in optimizing medical care for pulmonary hypertension. Third, accurate evaluation of wall shear stress may be helpful in predicting graft patency after CABG. Lastly, mechanical ventricular unloading using LVAD may be useful in improving the outcome of patients with acute MI.

Diagnostic and therapeutic methods for cardiovascular diseases will continue to be developed in the 21st century. Insight into the physiological characteristics of the cardiovascular system is necessary for optimal uses of newly developed drugs and devices in patients with cardiovascular diseases. Clinical development of diagnostic and therapeutic modalities for cardiovascular diseases should be based on physiological insights of the cardiovascular system.
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